BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17536870)

  • 1. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
    Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
    Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
    van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM
    J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.
    Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M
    J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.
    Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG
    J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
    van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
    Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
    Geller DE; Rosenfeld M; Waltz DA; Wilmott RW;
    Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
    Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
    J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
    [No Abstract]   [Full Text] [Related]  

  • 16. Eradication of early P. aeruginosa infection in children <7 years of age with cystic fibrosis: The early study.
    Ratjen F; Moeller A; McKinney ML; Asherova I; Alon N; Maykut R; Angyalosi G;
    J Cyst Fibros; 2019 Jan; 18(1):78-85. PubMed ID: 29685813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
    Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
    Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.